Gilead's (GILD) Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. CBRS
2. FDX
3. KBH
4. HON
5. HTZ
6. MRK
7. TTWO
8. USO
9. QCOM
10. INFY

Go back to Gilead's (GILD) Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients
Gilead Sciences (NASDAQ: GILD) Delayed: 125.05 --0 (-0%)
Previous Close $125.05    52 Week High $108.63 
Open $125.05    52 Week Low $71.39 
Day High $125.05    P/E 69.09 
Day Low $125.05    EPS $1.81 
Volume 3,923